1 citations
,
October 1971 in “The BMJ” The document suggests that hair loss after stopping birth control may be similar to post-pregnancy hair loss and could recur with future pregnancies.
January 2025 in “Dermatologic Therapy” Baricitinib effectively promotes hair regrowth in alopecia areata patients with mild side effects.
February 2025 in “Pharmaceuticals” Myo-inositol with magnesium effectively reduces acne and hirsutism in PCOS patients without side effects.
1 citations
,
December 2015 in “Endocrinology” Decanoic acid may help treat PCOS by reducing androgen levels and improving glucose sensitivity.
6 citations
,
May 2023 in “Drugs” Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.
23 citations
,
October 2024 in “British Journal of Dermatology” Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.
1 citations
,
August 2022 in “JAAD case reports” Pioglitazone use was linked to hair regrowth in a patient with permanent hair loss from cicatricial alopecia.
Individualized treatment improves symptoms and quality of life for women with PCOS.
December 2024 in “Frontiers in Pediatrics” Baricitinib improved platelet counts and alopecia in a 16-year-old with chronic immune thrombocytopenia.
1 citations
,
November 2011 in “Open access journal of contraception” Birth control pills with low-dose estrogen and antiandrogenic progestins can effectively treat acne.
2 citations
,
February 2025 in “Allergies” Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.
March 2023 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib helped most alopecia areata patients regrow hair by Week 48.
9 citations
,
April 2021 in “Expert opinion on pharmacotherapy” Clascoterone is a new, effective, and safe acne treatment without systemic side effects.
Baricitinib effectively promotes regrowth of eyebrows and eyelashes in alopecia areata patients.
1 citations
,
October 2025 in “Scientific Reports” Sonidegib and vismodegib have different side effects and reporting patterns.
February 2024 in “Journal of the European Academy of Dermatology and Venereology” Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.
1 citations
,
April 2008 in “Progrès en Urologie” Systematic end-of-trial biopsies are the most reliable way to assess outcomes.
The document helps doctors recognize and treat excessive hair growth in women.
1 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ritlecitinib effectively regrows and maintains scalp, eyebrow, and eyelash hair in alopecia areata patients.
7 citations
,
August 2017 in “European journal of endocrinology” Mutations in the POC1A gene can cause a unique form of extreme insulin resistance and short stature.
3 citations
,
March 2025 in “Journal of Clinical Medicine” Ritlecitinib effectively treats alopecia areata with manageable side effects.
October 2025 in “Journal of Obstetric and Gynaecological Practices POGS”
August 2002 in “Analytical Sciences” The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.
30 citations
,
April 2007 in “Dermatologic Clinics” The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.
July 2023 in “SKIN The Journal of Cutaneous Medicine” Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
4 citations
,
March 2023 in “IP International Journal of Comprehensive and Advanced Pharmacology” The new drug delivery system improves exemestane's absorption and effectiveness.
July 2024 in “International Journal of Chemical and Biological Sciences” Glypican-4 may help indicate insulin sensitivity and lipid issues in women with PCOS.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Baricitinib significantly regrows hair in severe alopecia areata patients.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
58 citations
,
November 2020 in “International Journal of Molecular Sciences” SHBG may be a useful early indicator and treatment target for PCOS.